Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy.

Lusa, Amanda; Alvarez, Carolina; Saxena Beem, Shruti; Schwartz, Todd A; Ishizawar, Rumey

Lusa, Amanda; Alvarez, Carolina; Saxena Beem, Shruti; Schwartz, Todd A; Ishizawar, Rumey.

Afiliación

Lusa A; Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA. amanda_lusa@med.unc.edu.
Alvarez C; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA.
Saxena Beem S; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA.
Schwartz TA; Department of Biostatistics, Gillings School of Global Public Health and Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA.
Ishizawar R; Division of Rheumatology, Allergy, and Immunology, University of North Carolina, Chapel Hill, NC, USA.

BMC Rheumatol ; 6(1): 64, 2022 Nov 08.

Article en En | MEDLINE | ID: mdl-36345032

Palabras clave

Anti-rheumatic therapy; Disease flare; Immune checkpoint inhibitor; Immune-related adverse event; Rheumatoid arthritis; Rheumatologic disease

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: BMC Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google